Dose-defining study of a NAT2 phenotpe-based dosing regimen of intravenous amonafide L-malate administered weekly in men with androgen-independent prostate cancer (AIPC)
Phase of Trial: Phase I/II
Latest Information Update: 21 Apr 2008
At a glance
- Drugs Amonafide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Apr 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
- 27 Oct 2005 New trial record.